SALL1 silencing decreased human primary AML cell proliferation, resulted in low AML engraftment into NSG mice, and correlated with the upregulation of PTEN and the downregulation of mTOR, β-catenin, and NF-қB expression. The gene discussed is SALL1; the disease is acute myeloid leukemia.